References
Patel, N.K. et al. Ann. Neurol. 57, 298–302 (2005).
Gill, S.S. et al. Nat. Med. 9, 589–595 (2003).
Langston, J.W. et al. Mov. Disord. 7, 2–13 (1992).
Patel, N.K. et al. Mov. Disord. 17 Suppl 9, 727 (2004).
Chalmers, K., Wilcock, G.K. & Love, S. Neuropathol. Appl. Neurobiol. 29, 231–238 (2003).
Opacka-Juffry, J. et al. Neuroreport 7, 348–352 (1995).
Tomac, A. et al. Nature 373, 335–339 (1995).
Date, I., Aoi, M., Tomita, S., Collins, F. & Ohmoto, T. Neuroreport 9, 2365–2369 (1998).
Kirik, D., Georgievska, B. & Bjorklund, A. Nat. Neurosci. 7, 105–110 (2004).
Acknowledgements
We thank C. Redman, R. Quilty, T. McLaren, M. Jennings and R. Barber for technical assistance. Amgen, Inc. supplied the GDNF for this trial.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Love, S., Plaha, P., Patel, N. et al. Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11, 703–704 (2005). https://doi.org/10.1038/nm0705-703
Issue Date:
DOI: https://doi.org/10.1038/nm0705-703
- Springer Nature America, Inc.
This article is cited by
-
Long-term benefits of hematopoietic stem cell-based macrophage/microglia delivery of GDNF to the CNS in a mouse model of Parkinson’s disease
Gene Therapy (2024)
-
SC79 promotes efficient entry of GDNF liposomes into brain parenchyma to repair dopamine neurons through reversible regulation of tight junction proteins
Nano Research (2023)
-
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia
Molecular Psychiatry (2022)
-
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies
Pharmacological Reports (2020)
-
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Neurotherapeutics (2020)